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ABSTRACT
Agouti-related peptide (AgRP) neurons of the hypothalamus play a role in hunger-triggered food intake, stability of body 
weight, and long-term energy balance. A recent study showed that activation of the Gs-linked G protein-coupled recep-
tors (GCPR) expressed by hypothalamic AgRP neurons promotes a sustained increase in food intake. Enhanced AgRP 
release has been the postulated underlying mechanism. Here, we confirmed that activation of Gs-coupled receptors 
expressed by AgRP neurons in the arcuate nucleus (ARC) of the hypothalamus, which is the primary brain region for the 
synthesis and release of AgRP, leads to increased release of AgRP in the paraventricular nucleus of the hypothalamus 
(PVN). We were unable to confirm changes in AgRP expression or intracellular content using traditional histological 
techniques. Thus, we developed an assay to measure AgRP in the extracellular fluid in the brain using large molecular 
weight cut-off microdialysis probes. Our technique enables assessment of brain AgRP pharmacokinetics under phys-
iological conditions and in response to specific pharmacological interventions designed to modulate AgRP signaling.
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INTRODUCTION
Obesity is a burgeoning health crisis in most parts of the world 
[1]. It is a major risk factor for many diseases such as type 2 diabetes, 
cancer, and cardiovascular disease [2]. Weight loss and management 
are difficult to achieve via behavioral approaches, and only a limited 
number of appetite-suppressing drugs show modest clinical efficacy. 
Thus, efforts are being made to identify neuronal circuits that regulate 
food intake in order to more selectively target the development of new 
therapeutics [3,4].
There is a growing body of evidence that the neuropeptide agou-
ti-related peptide (AgRP), which is expressed exclusively in the arcuate 
nucleus (ARC) of the hypothalamus, plays a critical role in controlling 
food intake, body weight and metabolism, and, most importantly, man-
aging the long term stability of body weight [5-7]. For example, the 
firing rate of AgRP neurons is elevated in brain slices of food-deprived 
mice [8], and ablation of AgRP neurons in adult mice leads to starvation 
[9,10]. Further, the neurotransmitters AgRP and neuropeptide Y (NPY), 
a peptide that coexists with AgRP, increase food intake when injected 
into the brain [11,12]. Optogenetic and chemogenetic methods can 
mimic endogenous regulation of AgRP neurons [6,13-19]. Optogenetic 
stimulation of AgRP neurons triggers a robust increase of food intake in 
well-fed mice [20]. DREADDs (designer receptors exclusively activated 
by designer drugs) are designer G-protein coupled receptors (GPCRs) 
that can be activated by clozapine-N-oxide (CNO), an otherwise phar-
macologically inert drug [21-24]. DREADD technology has been used 
to activate AgRP neurons through the Gq- and Gs-mediated signaling 
pathway [6,19] which mimic the activity of endogenous ghrelin and 
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PAC1 receptors at AgRP neurons [25]. Similar to light activation, Gq or 
Gs DREADD stimulation of AgRP neurons leads to robust food intake, 
even during the light cycle when food intake is typically restricted [6,19].
It remains unclear how GPCRs signaling in AgRP neurons in the 
ARC affects the release of AgRP in brain regions monosynaptically 
connected to and down-stream from these neurons, such as the para-
ventricular nucleus (PVN) of the hypothalamus. This is due to the 
challenges of developing an assay to monitor the in vivo kinetics of 
AgRP, a large molecule (112 amino acids). Thus, the purpose of this 
study was to determine whether excitation of AgRP neurons in the ARC 
by DREADD technology triggers AgRP release in the PVN. Microdi-
alysis is a sampling technique which has been extensively used for the 
characterization and assessment of the in vivo pharmacokinetic profile 
of drugs and neurotransmitters in rodents and non-human primates. 
Recently, with the availability of larger pore membrane probes and the 
push-pull method, in vivo microdialysis has been used to detect relatively 
large peptides in the brain (e.g., apolipoprotein E [26]; tau protein [27]; 
amyloid β [28]). We took advantage of this technique and investigated 
AgRP release in the PVN after DREADD-mediated activation of the 
Gs pathway in AgRP neurons. Here we report the successful monitoring 
of AgRP level in the mouse PVN via microdialysis.
MATERIALS AND METHODS
Animals and viruses
All experiments were conducted according to US National Institutes 
of Health guidelines for animal research and were approved by the 
NIDDK Institutional Animal Care and Use Committee. Twenty-four 
AgRP-ires-cre mice (Agrptm1(cre)Lowl/J; The Jackson Laboratory, 
stock #012899) were randomly divided into two groups and were 
injected bilaterally with either an adeno-associated virus encoding 
Gs–DREADD (AAV8-hSyn-DIO-Rs-eGFP (AV4557, titer 8 × 10
12)) or 
a control virus (AAV8-hSyn-DIO-GFP (AV4937, titer 2 × 1012) into the 
ARC. Both AAVs were obtained from the UNC Vector Core Facility. 
Microdialysis probes were placed in the PVN during a second surgery 
6 weeks after the viral injections.
Viral injections
Male mice (at least 8 weeks old) were anaesthetized with isoflurane 
and placed into a stereotaxic apparatus (David Kopf Instruments, model 
940A with 923B mouse gas anesthesia head holder). The skull was 
exposed via a small incision, and holes were drilled (0.45 mm drill 
bits) into the skull. A 5 μl Hamilton syringe with a 33 gauge, blunt-end 
needle was inserted into the brain, and bilateral pressure injections of 
the AAV were administered targeting the ARC (Bregma: −1.46 mm AP; 
± 0.3 mm ML; −5.80 mm DV). The injection volume was 200–300 nl 
depending on the titers of different viruses. Postoperative analgesia 
was provided (ketoprofen, 5 mg/kg i.p.).
In vitro microdialysis
The microdialysis probe used for in vitro study had an 8 mm shaft 
with a 1 mm, 1000 kDa molecular weight cutoff (MWCO) polyethylene 
(PE) membrane (PEP-8-01, Eicom, Kyoto, Japan). The probe was 
prepared by flushing it first with distilled water and then with artificial 
cerebrospinal fluid (aCSF) perfusion solution. The probe’s inlet and outlet 
were then connected to a microsyringe pump (kdScientific, KDS-250) 
and a peristaltic pump (LongerPump, BT100-2J with DG4-10 head), 
respectively, using polyethylene tubing (PE-20, 380 μm ID). Sampling 
was carried out at different flow rates (0.5–2.0 μl/min). Probes were 
placed into AgRP solutions of known concentrations (60 and 600 pg/
ml), and samples were collected every 50 min and stored at −80°C 
until being processed.
In vivo microdialysis
Mice were anaesthetized using 2.5% tribromoethanol (Avertin®) and 
placed into a stereotaxic apparatus. Before the probes were implanted, 
a small incision was made to expose the skull, the head position was 
leveled using bregma and lambda as reference points, and a small hole 
was drilled for injections and implants. Probes were connected to the 
perfusion system as described for the in vitro microdialysis experiment. 
The pump speeds were calibrated such that the fluid perfused through 
the probes at a 1 μl/min flow rate. Finally, the probe was implanted in 
the PVN (bregma: −0.75 mm AP; 0.13 mm ML; −5.60 mm DV) and 
fixed using an anchoring bone screw and dental cement.
Mice were given 24 h to recover, then dialysate samples were collected 
every 50 min for about 2 h to establish an equilibrium between the inside 
and outside of the microdialysis membrane and acclimate the mice to 
the collection procedure (Fig. 1). Baseline samples were collected over 
50 min. Mice then received a CNO injection (1 mg/kg i.p.), and the 
perfusion solution was allowed to flow through the probe for 30 min 
before the post-CNO samples were collected, at 1 and 24 h. Samples 
were collected into vials containing 5 µl 0.1 N HCl and immediately 
frozen on dry ice. All samples were stored at −80°C until processed, 
and all stereotaxic sites were histologically verified.
Figure 1. Graphical time-line of experimental procedure for Gs-DREADD activation of AgRP neurons and real-time in vivo microdialysis col-
lection in mice. Eight-weeks after viral injections into the ARC and twenty-four hours after microdialysis probe implant into the PVN, mice underwent a 
dialysate collection protocol which included 50 min sampling at baseline and 1 and 24 h after CNO or saline administration.
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AgRP ELISA
Dialysate samples from 10 mice were collected, and AgRP concen-
trations were measured in these samples using a mouse enzyme immu-
noassay kit (US Biological, 023199). However, prior to the assay, one 
sample from two mice, matched by condition (i.e., baseline or 1 h- or 
24 h-post CNO injection), were randomly paired and pooled to yield the 
required sample volume and detectable concentrations for the ELISA 
kit. The detection limit of the enzyme immunoassay kit was 4.69 pg/ml 
with a sensitively of 1.83 pg/ml. The intra-assay CV was 1.44% and 
3.70%, respectively.
Immunohistochemistry and imaging
To inhibit axonal transport and enhance our ability to visualize 
AgRP by immunohistochemical (IHC) staining, 30 µg of colchicine in 
5 µl of physiological saline was delivered under anesthesia at a flow 
rate of 500 ng/min intracerebroventricularly (bregma: −0.34 mm AP; 
−1.0 mm ML; −3.0 mm DV). The mice were returned to their home 
cage and left undisturbed for 24 h. Then, mice were perfused with 
4% paraformaldehyde in 0.1 M phosphate buffer fixative (pH 7.4), 
and brains were harvested and postfixed in this solution overnight. 
Mouse brains were sliced with a vibratome (Leica VT1000S) at 30 µm 
thickness and stored in 4°C in PBS until assayed. For IHC staining, 
brain slices were incubated overnight at 4°C with primary antibodies 
(either anti-AgRP, 1:1000, H-003-57, Phoenix Pharmaceuticals, INC 
or anti-GFP, 1:400, ab6662(FITC)) diluted in PBS, supplemented with 
1% BSA and 0.1% Triton X-100. Slices were then washed three times 
and incubated with species appropriate and minimally cross-reactive 
fluorophore-conjugated secondary (Abcam; Donkey anti rabbit IgG 594, 
1:000, ab150064, Abcam; goat anti rabbit 594, 1:1000) for 2 h at room 
temperature. Slices were rinsed in PBS with 0.1% Triton X-100 three 
times and mounted for imaging using Antifade Reagent (SlowFade® 
Gold with DAPI, S36939). Fluorescence images were taken with Zeiss 
and Leica fluorescent microscopes.
RNAScope method to detect AgRP expression in the 
ARC
Fresh frozen mouse brains were collected and stored at −80°C, then 16 
µm sections were cut with a cryostat and mounted onto superfrost slides 
and stored at −80°C. The 2-plex 2.0 kit was used for RNAScope assays. 
Following the manufacturer’s (Advanced Cell Diagnostics) protocol, 
sections on the slides were fixed at room temperature with 10% NFB 
for 30 min, dried with 50%, 70% and 100% ethanol. The edges of the 
slides were marked with a waterproof pen. Pretreatment steps included 
room temperature incubations with pretreatment solution 1 (10 min), 
pretreatment solution 2 (10 min), and pretreatment solution 3 (30 min). 
Sections were hybridized at 40°C for 2 h with a specifically designed 
AgRP probe. Finally, sections were exposed to serial amplification steps 
(AMP1 through AMP6), color development, counterstaining with 10% 
hematoxylin, and dried by using a 65°C heat block. Cover slides were 
placed over the sections on the slide with Ecomount, and images were 
captured and processed with a Keyence Digital Microscope.
Statistical analysis
Statistical analyses were performed using IBM SPSS Statistics 19 
(SPSS, Inc., an IBM Company) and were expressed as mean ± SEM. 
Normality was tested using Kolmogorov-Smirnov. Outliers were assessed 
using the IQR (interquartile range) method, denoting values three times 
below the 1st quartile or above the 3rd quartile as outliers. No sample 
calculation was performed.
RESULTS
Gs DREADD selectively expressed in ARC AgRP neu-
rons without altering AgRP expression
We injected Gs–DREADD or AAV-hSyn-DIO-GFP viruses into male 
AgRP-ires-cre mice and eight weeks later visualized the expression using 
IHC to visualize viral GFP expression. GFP expression was localized to 
cell bodies in the ARC and colocalized with AgRP expression, confirm-
ing that viral expression was selective to AgRP neurons (Fig. 2). AgRP 
protein and mRNA expression were quantified to determine if viral 
administration affected these parameters. However, neither Gs–DREADD 
nor AAV-hSyn-DIO-GFP administration influenced AgRP protein or 
mRNA levels, visualized by IHC and RNAScope, respectively (Fig. 3).
In vitro microdialysis
We selected a microdialysis probe membrane (1000 kDa MWCO, 
PEP-8-01, Eicom, Kyoto, Japan) suitable for collecting high-molecular 
weight molecules, as AgRP has a molecular mass of ~14 kDa. There was 
an inverse relationship between flow rate and percentage recovery for 
AgRP at a low and a high concentration, 60 and 600 pg/ml respectively 
(flow rate: 0.5 μl/min, 26.0% recovery; 1.0 μl/min, 17.6% recovery; 
2.0 μl/min, 6.5% recovery) (Fig. 4). Based on these results, we decided 
to use the 1.0 μl/min flow rate for in vivo microdialysis experiments 
(see next paragraph).
In vivo microdialysis
To determine if Gs activation increased AgRP release, we used che-
mogenetic technology and real-time in vivo microdialysis to stimulate 
AgRP neurons in the ARC and measure subsequent AgRP release in the 
PVN. Specifically, we bilaterally injected the Gs-DREADD virus into 
the ARC of AgRP-ires-Cre mice to express the Gs-linked DREADD 
in AgRP ARC neurons (Fig. 2). Eight weeks later, the extracellular 
fluid from the PVN was collected to measure the AgRP concentrations 
before and after (1 h- and 24 h-post) CNO injections. Extracellular 
AgRP concentrations were measured 94.07 ± 2.65 pg/ml in the sa-
line-treated mice and 90.71 ± 6.93 pg/ml in the CNO-treated mice. 
CNO-mediated excitation of AgRP ARC neurons markedly enhanced 
the release of AgRP in the PVN during the first hour (t(4) = 5.52, P < 
0.005) following the CNO injection but not 24 h later (t(4) = 0.29, P 
= 0.79) (Fig. 4). Control mice received either the Gs-DREADD virus 
without CNO treatment (saline + DREADD; virus control) or were 
treated with CNO in the absence of Gs-DREADD expression (CNO + 
AAV-hSyn-DIO-GFP; drug control). No effects on AgRP release were 
observed for either control group.
DISCUSSION
In this study, we used in vivo microdialysis with a unique large-pore-
sized membrane probe (1000-kDa MWCO) and push-pull perfusion system 
to monitor AgRP extracellular levels in the PVN, a major target region of 
hypothalamic AgRP neurons. To the best of our knowledge, this is the first 
report that has demonstrated the detection and characterization of AgRP 
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release in the brain, which is important to determine the function of AgRP signaling in regulation of food intake, metabolism, and body weight.
Figure 2. Viral expression is localized to AgRP neurons in the arcuate nucleus. A. AgRP immunostaining shows AgRP expression in the arcuate 
nucleus following Cre-inducible AAV-hSyn-DIO-Rs-eGFP (Gs–DREADD) injection in AgRP-ires-cre mice. B. AgRP immunostaining shows AgRP ex-
pression at axon projection to paraventricular nucleus of the hypothalamus. C-E. A series of 20× images of coronal sections in the ARC of Gs–DREADD 
treated mice illustrating (C) GFP+, (D) AgRP expression (AgRP+, 30 µg of colchicine was injected into the lateral ventricles of mice 24 h before perfusion 
to enhance AgRP concentration and allow visualization of cell bodies), and (E) colocalization of both proteins. Scale bar = 100 um.
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Figure 3. AgRP expression is not affected by Gs stimulation via the DREADD system. A and B. The 10× images of coronal sections show the 
expression of green fluorescent protein (GFP+, green) following either Cre-inducible AAV-hSyn-DIO-Rs-eGFP (Gs–DREADD) or AAV- hSyn-DIO-GFP 
(control virus) injection in the ARC of AgRP-ires-cre mice, respectively. C and D. Additional images of coronal sections at 40× following the same viral 
preparations as in panels (A) & (B). E and F. AgRP mRNA expression in the ARC after CNO treatment is similar between Gs–DREADD and control virus 
injected mice (A, C, E = Gs–DREADD virus; B, D, F = control virus). Scale bar = 100 um.
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Figure 4. Real-time pull-push microdialysis with a large-pore-sized membrane probe proved sensitive enough to detect AgRP release in the 
PVN after Gs–DREADD stimulation of AgRP neurons in the ARC. A. There was an inverse relationship between flow rate and percentage recovery 
for AgRP at a low and high concentration in the in vitro collection of AgRP via the large-pore-sized membrane probe and push-pull microdialysis system. 
Each value constitutes a single sample measured. B. Schematic drawing (left) and representative photomicrograph of the mouse brain section (right) 
illustrate location of microdialysis probe placement in the PVN. C. Excitation of AgRP ARC neurons markedly enhanced the release of AgRP in the PVN 
during the first hour following the CNO injection but not 24 h later (CNO + DREAAD). Control mice were generated as either Gs-DREADD virus injected 
without CNO treatment (saline + DREAAD; virus control) or control virus inject with CNO treatment (CNO + GFP). No effects on AgRP release were 
observed for either control group. Each value constitutes 4–5 samples tested in replication and are reported as mean and standard error. * denotes a 
significant change from baseline (P < 0.05).
In vitro microdialysis
Microdialysis is a widely used technique to measure the release of 
neurotransmitters and other small molecules in the brain [29]. Low 
MWCO microdialysis probes (typically 6–18 kDa) prohibit collection 
of relatively large-sized molecules with efficiency, including peptides 
near the MWCO such as AgRP (~14 kDa MW). Several recent reports 
have demonstrated that the use of high MWCO microdialysis probes 
improves collection of larger molecules and peptides (e.g., apolipoprotein 
E [26]; tau protein [27]; amyloid β [28]). Here, we first characterized 
the efficiency of AgRP collection from aCSF using microdialysis in 
vitro. The recovery of AgRP by microdialysis was inversely related to 
the flow rate through the microdialysis probe, which is consistent with 
measurements of other analytes [29]. We determined that a 1.0 µl/min 
flow rate yields the best recovery rate within the largest sample volume.
In vivo microdialysis
Our in vivo microdialysis work confirmed that activation of Gs 
signaling in AgRP neurons activation increased release of AgRP in the 
PVN. Specifically, we were able to selectively express a Gs DREADD 
in AgRP neurons in the ARC, which was confirmed to also express in 
axonal fibers in the PVN. Using site-specific injections of CNO into the 
PVN, the AgRP concentration in the PVN was increased an hour later. 
PVN AgRP levels returned to baseline within 24 h after stimulation. 
Recent studies showed that CNO can convert in vivo into clozapine, 
which has binding affinity and potency to targets other than DREADD 
[30]. Thus, to exclude non-specific outcomes of CNO metabolite action, 
we administered CNO into the PVN of DREADD-free mice, which did 
not affect local AgRP concentrations. Previous studies indicate that 
AgRP affects hunger-triggered food intake, stability of body weight, 
and long-term energy balance [5-7], which may occur, at least in part, 
through signaling via Gs-linked GPCRs on AgRP neurons in the ARC 
[19]. There are several brain regions downstream of the ARC AgRP 
neurons that have garnered attention regarding food intake research, such 
as PVN, bed nucleus of the stria terminalis and lateral hypothalamus. 
The methods developed here will be useful in sampling AgRP in the 
extracellular fluid of these brain regions over time in order to assess 
the relationship between AgRP levels and feeding behaviors and the 
role of Gs-linked GPCRs in mediating these processes.
Several studies have shown that AgRP neuron activation alone is 
sufficient to trigger robust food intake [6,19,20], which has led to the 
characterization of these neurons as ‘hunger neurons’ [7,31,32]. Still, 
how precisely the activation of AgRP neurons initiates feeding is still 
under investigation. There is evidence that gamma-Aminobutyric acid 
(GABA) release from these neurons is a rapid response to inhibit down-
stream neurons to trigger robust feeding acutely. In contrast, Krashes 
and colleagues demonstrated that the AgRP-induced food intake is 
impaired by double inactivation of both the GABA and NPY systems, 
but the effect only lasted only for a few hours [31]. This suggests that 
AgRP release may play an important role in long term food intake. In 
fact, it has recently been reported that Gs pathway activation, with the 
same DREADD system used in the current study, promotes food intake 
that lasts for days and mimics the effects of i.c.v. AgRP administration 
[19]. In contrast, stimulation of Gq pathway with a similar DREADD 
system (i.e., CNO-treated hM3Dq-AgRP mice) lasted only for a single 
day. This may result from the difference in cellular activity caused by 
the activation of Gs- versus Gq-dependent signaling pathways, which 
may also be reflected in distinct patterns of AgRP release. The effect 
of Gs activation could be blocked by a selective anti-AgRP antibody. In 
this study, we clearly demonstrated in vivo that Gs activation increases 
the release of AgRP in the PVN. Thus, enhancing AgRP release or Gs 
signaling in AgRP neurons may represent a useful strategy to develop 
novel appetite-suppressing drugs.
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